INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar

Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595

GlobeNewsWire • Feb 23, 2026

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study

GlobeNewsWire • Feb 19, 2026

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce time to market

GlobeNewsWire • Feb 10, 2026

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO:

GlobeNewsWire • Jan 27, 2026

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune's CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was published in the peer-reviewed journal Cytotherapy. One of the lead authors of the paper was INmune Bio's lead scientist for CORDStrom™ R&D, Dr Nikita M. Patel, M.Sci.,Ph.D.

GlobeNewsWire • Dec 5, 2025

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer's Disease conference (CTAD), being held on December 1-4, 2025 in San Diego, CA.

GlobeNewsWire • Dec 1, 2025

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer's Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.

GlobeNewsWire • Nov 18, 2025

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research • Nov 6, 2025

INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript

INmune Bio, Inc. ( INMB ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Daniel Carlson David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Chief Scientific Officer & Chief Manufacturing Officer CJ Barnum Cory Ellspermann - Interim Chief Financial Officer Conference Call Participants Denis Reznik - Raymond James Ltd., Research Division Jason Mccarthy - Maxim Group LLC, Research Division Presentation Operator " Daniel Carlson " David Moss President, CEO, Treasurer, Secretary & Director " Mark Lowdell Chief Scientific Officer & Chief Manufacturing Officer " CJ Barnum " Cory Ellspermann Interim Chief Financial Officer " Denis Reznik Raymond James Ltd.

Seeking Alpha • Oct 31, 2025

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update.

GlobeNewsWire • Oct 30, 2025